Here's why the Creso Pharma (ASX:CPH) share price is up 7%

Good news out of the Creso Pharma camp this morning.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Creso Pharma Ltd (ASX: CPH) share price has climbed well into the green in early trade today.

Cresco Pharma shares are now exchanging hands at 11.75 cents apiece, an almost 7% gain from the open.

What is Creso Pharma?

Creso Pharma develops and commercialises pharmaceutical cannabis and psychedelic compounds to treat health and medical conditions.

The company has a wide footprint across Switzerland, Australia, Canada, Colombia and Israel, but realises most revenue from Europe and the Middle East.

Creso Pharma has a market capitalisation of $131 million at the time of writing.

What's behind today's gains?

Creso provided an update on "operational progress" achieved through its Canadian subsidiary, Halucenex Life Sciences.

Halucenex is a research company focused on developing novel psychedelic compounds. These products are then sold to the pharmaceutical markets.

Creso announced that Halucenex has completed all satisfactory requirements for USP 61 microbial enumeration testing.

This is a significant milestone that demonstrates Creso's psilocybin compound is of pharmaceutical grade and safe from microbial nasties.

Furthermore, the company announced it had "commenced USP 62 protocols".

That is a similar test that examines pharmaceutical products for the presence of additional pathogens and other microbes.

It is an essential phase of any route to market in the pharmaceutical industry because the product must be deemed fit for humans.

Creso seems confident the test will "deem the company's products safe for human consumption" if successful.

What else does this mean?

Moreover, if successful, it will progress Halucenex's clinical trial authorisation (CTA) with Health Canada, helping to move forward its clinical trial pipeline.

Receiving the CTA allows the company to commence its phase II efficacy trial investigating the use of psilocybin in the treatment of post-traumatic stress disorder (PTSD).

Creso estimates the PTSD therapeutics market is worth "upwards of US$10.5 billion by 2025" and the company intends to "grow its market share across the sector" in the coming periods.

Market sentiment around clinical trial progress is a major force that drives share price returns in biotech and biopharma companies. That means good news is reflected on the charts for these shares.

In addition, Creso also released its quarterly update on Monday which shot its share price 9% higher on the day.

It stands to reason these two factors are behind the movement in the Creso Pharma share price today.

Creso Pharma share price snapshot

The Creso Pharma share price has posted a loss of 35% since January 1 this year. Over the last month, Creso shares have dipped 13% into the red.

Despite this, Creso shares have still climbed 279% into the green over the past 12 months.

This has outpaced the S&P/ASX 200 Index (ASX: XJO)'s return of around 26% over the past year.

Contributor Zach Bristow has no position on any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

A man sits on a bench atop a mountain with a laptop, making investments with a green ESG mind.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors endured a day to forget this hump day.

Read more »

A young woman holding her phone smiles broadly and looks excited, after receiving good news.
Share Gainers

Why Droneshield, Meteoric Resources, Mount Gibson, and Tyro shares are charging higher

These shares are having a good time on hump day. But why?

Read more »

Ten smiling business people wave to the camera after receiving some winning company news.
Share Gainers

Here are the top 10 ASX 200 shares today

The ASX was back in the black this Tuesday.

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Share Gainers

Why DroneShield, Hansen, Hub24, and Paladin Energy shares are racing higher today

These shares are having a strong session. Let's find out why.

Read more »

Man on a laptop thinking.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors weren't in a good mood this Monday.

Read more »

a young woman raises her hands in joyful celebration as she sits at her computer in a home environment.
Share Gainers

Why Abacus Storage King, DroneShield, Hansen, and Macquarie Technology shares are charging higher

These shares are starting the week on a positive note. But why?

Read more »

A man looking at his laptop and thinking.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors finished the trading week on a sour note today.

Read more »

Happy teen friends jumping in front of a wall.
Share Gainers

4 ASX 200 stocks smashing the benchmark this week

Investors are sending these four ASX 200 stocks soaring this week. But why?

Read more »